Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price reached a new 52-week low on Thursday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 17000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The company has a market capitalization of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The business’s 50-day simple moving average is C$0.01 and its two-hundred day simple moving average is C$0.01.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Read More
- Five stocks we like better than Aequus Pharmaceuticals
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- What is a Low P/E Ratio and What Does it Tell Investors?
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
